Posted on 335
Eleusis Ltd, a clinical-stage life science company dedicated to unlocking the full therapeutic potential of psychedelics, today announced that it has appointed David E. Nichols, Ph.D., a renowned expert on the pharmacology and medicinal chemistry of psychedelics, as its Director of Molecular Pharmacology. He will collaborate closely with his son, Charles Nichols, Ph.D., the scientific founder of Eleusis, in an effort to accelerate the transformation of psychedelics into medicines.
Dr. David Nichols is an Adjunct Professor at the University of North Carolina Chapel Hill, where he continues research. Prior to his retirement, he served as Distinguished Professor of Medicinal Chemistry and Molecular Pharmacology, and as the Robert C. and Charlotte P. Anderson Distinguished Chair in Pharmacology at Purdue University. He is the founding president of the Heffter Research Institute, which was instrumental in the c
(1)
Acquisition of Kalypso accelerates the clinical development of psychedelic infusion therapies
ELE-Ket+ and ELE-Psilo+ are psychedelic infusion therapies in clinical development for adjunctive treatment of major depressive disorder;
initiation of Phase 2 clinical trials expected in Q4 2021 Eleusis Ltd, a clinical-stage life science company dedicated to unlocking the full therapeutic potential of psychedelics, today announced the launch of its clinical development of psychedelic infusion therapies and acquisition of Kalypso Wellness Centers ( Kalypso ), a leading provider of ketamine infusion therapies in the United States. Under the terms of the agreement, Eleusis will acquire Kalypso and its intellectual property in an all-stock transaction.